These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16804935)

  • 1. Delayed profound thrombocytopenia associated with eptifibatide.
    Onitilo AA
    Am J Hematol; 2006 Dec; 81(12):984. PubMed ID: 16804935
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eptifibatide-induced thrombocytopenia and thrombosis.
    Epelman S; Nair D; Downey R; Militello M; Askari AT
    J Thromb Thrombolysis; 2006 Oct; 22(2):151-4. PubMed ID: 17008982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.
    Coto H
    J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
    Sharma A; Ferguson C; Bainey KR
    Can J Cardiol; 2015 Jun; 31(6):809-11. PubMed ID: 25913474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe thrombocytopenia possibly related to readministration of eptifibatide.
    Paradiso-Hardy FL; Madan M; Radhakrishnan S; Hurden S; Cohen EA
    Catheter Cardiovasc Interv; 2001 Sep; 54(1):63-7. PubMed ID: 11553950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer.
    Pothineni NV; Watts TE; Ding Z; Dai Y; Deshmukh AJ
    Am J Ther; 2016; 23(1):e298-9. PubMed ID: 24368608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia.
    Greinacher A; Fuerll B; Zinke H; Müllejans B; Krüger W; Michetti N; Motz W; Schwertz H
    Blood; 2009 Aug; 114(6):1250-3. PubMed ID: 19429867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia.
    Yang EH; Perez E; Zhiroff KA; Burstein S
    Tex Heart Inst J; 2011; 38(2):174-8. PubMed ID: 21494531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptifibatide in acute coronary syndromes.
    Moll S
    N Engl J Med; 1999 Jan; 340(1):60-1. PubMed ID: 9882215
    [No Abstract]   [Full Text] [Related]  

  • 11. Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.
    Tempelhof MW; Benzuly KH; Fintel D; Krichavsky MZ
    Tex Heart Inst J; 2012; 39(1):86-91. PubMed ID: 22412237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eptifibatide-Induced Profound Thrombocytopenia After Percutaneous Intervention for Acute Coronary Syndrome: A Challenging Clinical Scenario.
    Bhatia N; Sawyer RD; Ikram S
    Methodist Debakey Cardiovasc J; 2017; 13(4):248-252. PubMed ID: 29744018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirofiban-induced acute profound thrombocytopenia after primary angioplasty.
    Dursunoglu D; Taskoylu O; Gür S; Sari I
    Asian Cardiovasc Thorac Ann; 2013 Feb; 21(1):74-6. PubMed ID: 23430426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
    Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute profound thrombocytopenia associated with readministration of eptifibatide: case report and review of the literature.
    Russell KN; Schnabel JG; Rochetto RP; Tanner MC
    Pharmacotherapy; 2009 Jul; 29(7):867-74. PubMed ID: 19558261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eptifibatide-induced acute profound thrombocytopenia: a case report.
    Graidis C; Golias C; Dimitriadis D; Dimitriadis G; Bitsis T; Dimitrelos I; Tsiakou A; Charalabopoulos K
    BMC Res Notes; 2014 Feb; 7():107. PubMed ID: 24564943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute thrombocytopenia associated with eptifibatide therapy.
    Khaykin Y; Paradiso-Hardy FL; Madan M
    Can J Cardiol; 2003 Jun; 19(7):797-801. PubMed ID: 12813613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute profound thrombocytopenia associated with eptifibatide therapy.
    Nagge J; Jackevicius C; Dzavik V; Ross JR; Seidelin P
    Pharmacotherapy; 2003 Mar; 23(3):374-9. PubMed ID: 12627937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.